Ubiquitinated inclusions and neuronal cell death

Histology and Histopathology

Volumn 18, Issue 2, 2003, Pages 509-517

  Lang Rollin, I ^a   Rideout, H ^a   Stefanis, Leonidas ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Apoptosis; Lewy body; Neurodegenerative; Parkinson's disease; Proteasome

Indexed keywords

ALPHA SYNUCLEIN; CASPASE; CELL CYCLE PROTEIN; DACTINOMYCIN; EPOXOMICIN; FIBRILLAR COLLAGEN; LACTACYSTIN; PROTEASOME; PROTEASOME INHIBITOR; PROTEIN KINASE; UBIQUITIN; UBIQUITIN CONJUGATING ENZYME;

APOPTOSIS; BRAIN CELL; CELL DEATH; DEGENERATIVE DISEASE; DIFFUSE LEWY BODY DISEASE; DRUG INHIBITION; GENETIC ASSOCIATION; HUMAN; MITOSIS INHIBITION; MUTANT; NERVE CELL; PARKINSON DISEASE; PATHOGENESIS; PATHOLOGY; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVIEW;

ALPHA-SYNUCLEIN; ALZHEIMER DISEASE; ANIMALS; CELL DEATH; HUMANS; INCLUSION BODIES; NERVE TISSUE PROTEINS; NEURODEGENERATIVE DISEASES; NEURONS; PARKINSON DISEASE; SYNUCLEINS; UBIQUINONE;

EID: 0037378117     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (96)

1. Amerik A.Y., Swaminathan S., Krantz B.A., Wilkinson K.D. and Hochstrasser M. (1997) In vivo disassembly of free polyubiquitin chains by yeast Ubp14 modulates rates of protein degradation by the proteasome. EMBO J. 16, 4826-4838.
2. Ancolio K., Alves Da Costa C., Ueda K. and Checler F. (2000) Alpha-synuclein and the Parkinson's disease-related mutant Ala53Thr-alpha-synuclein do not undergo proteasomal degradation in HEK293 and neuronal cells. Neurosci. Lett. 285, 79-82.
3. Auluck P.K., Chan H.Y., Trojanowski J.Q., Lee V.M. and Bonini N.N. (2002) Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease. Science 295, 865-868.
4. Banerjee A., Deshaies R.J. and Chau V. (1995) Characterization of a dominant negative mutant of the cell-cycle ubiquitin-conjugating enzyme Cdc34. J. Biol. Chem. 270, 26209-26215.
5. Bence N.F., Sampat R.M. and Kopito R.R. (2001). Impairment of the ubiquitin-proteasome system by protein aggregation. Science 292, 1552-1555
6. Bennett M.C., Bishop J.F., Leng Y., Chock P.B., Chase T.N. and Mouradian M.M. (1999) Degradation of alpha-synuclein by proteasome. J. Biol. Chem. 274, 33855-33858.
7. Chain D.G., Schwartz J.H. and Hegde A.N. (1999). Ubiquitin-mediated proteolysis in learning and memory. Mol. Neurobiol. 20, 125-142.
8. Checler F., Da Costa C.A., Ancolio K., Chevallier N., Lopez-Perez E. and Marambaud P. (2000) Role of the proteasome in Alzheimer's disease. Biochim. Biophys. Acta 1502, 133-138.
9. Chung K.K., Zhang Y., Lim K.L., Tanaka Y., Huang H., Gao J., Ross C.A., Dawson V.L. and Dawson T.M. (2001a). Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: Implications for Lewy-body formation in Parkinson disease. Nat. Med. 7, 1144-1150.
10. Chung K.K., Dawson V.L. and Dawson T.M. (2001b). The role of the ubiquitin-proteasomal pathway in Parkinson's disease and other neurodegenerative disorders. TINS 24, S7-S14.
11. Ciechanover A. (1998). The ubiquitin-proteasome pathway: On protein death and cell life. EMBO J. 17, 7151-7160.
12. Clarke P.G. (1990). Developmental cell death: Morphological diversity and multiple mechanisms. Anat. Embryol. (Berl) 181, 195-213.
13. Clayton D.F. and George J.M. (1999) Synucleins in synaptic plasticity and neurodegenerative disorders. J. Neurosci. Res. 58, 120-129.
14. Conway K.A., Harper J.D. and Lansbury P.T. (1998). Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat. Med. 4, 1318-1320.
15. Cordato N.J., Halliday G.M., Harding A.J., Hely M.A. and Morris J.G. (2000). Regional brain atrophy in progressive supranuclear palsy and Lewy body disease. Ann. Neurol. 47, 718-728.
16. Cummings C.J., Mancini M.A., Antalffy B., DeFranco D.B., Orr H.T. and Zoghbi H.Y. (1998). Chaperone suppression of aggregation and altered subcellular proteasome localization imply protein misfolding in SCA1. Nat. Genet. 19, 148-154.
17. Drexler H. (1997). Activation of the cell death program by inhibition of proteasome function. Proc. Natl. Acad. Sci. USA 94, 855-860.
18. Duda J.E., Lee V.M. and Trojanowski J.Q. (2000). Neuropathology of synuclein aggregates. J. Neurosci. Res. 2000 6, 121-127.
19. Engelender S., Kaminsky Z., Guo X., Sharp A.H., Amaravi R.K., Kleiderlein J.J., Margolis R.L., Tronsoco J.C., Lanahan A.A., Worley P.F., Dawson V.L., Dawson T.M. and Ross C.A. (1999). Synphilin-1 associates with alpha-synuclein and promotes the formation of cytosolic inclusions. Nat. Genet. 22, 110-114.
20. Fahn S. (1995). Parkinsonism. In: Merritt's Textbook of Neurology. 9th ed. Rowland L.P. (ed). Williams & Wilkins. Philadelphia. pp 713-730.
21. Feany M.B. and Bender W.W. (2000). A Drosophila model of Parkinson's disease. Nature 404, 394-398.
22. Fenteany G. and Schreiber S.L. (1998). Lactacystin, proteasome function, and cell fate. J. Biol. Chem. 273, 8545-8548.
23. Figueiredo-Pereira M., Berg K. and Wilk S. (1994). A new inhibitor of the chymotrypsin-like activity of the multicatalytic proteinase complex (20S Proteasome) induces accumulation of ubiquitin-protein conjugates in a neuronal cell. J. Neurochem. 63, 1578-1581.
24. Fraser P.E., Levesque G., Yu G., Mills L.R., Thirlwell J., Frantseva M., Gandy S.E., Seeger M., Carlen P.L. and St. George-Hyslop P. (1998) Presenilin 1 is actively degraded by the 26S proteasome. Neurobiol. Aging. 19(1 Suppl), S19-21.
25. Furlong R.A., Narain Y., Rankin J., Wyttenbach A. and Rubinsztein D.C. (2000). Alpha-synuclein overexpression promotes aggregation of mutant huntingtin. Biochem. J. 15, 577-581.
26. Ghee M., Fournier A. and Mallet J. (2000). Rat alpha-synuclein interacts with tat binding protein 1, a component of the 26S proteasomal complex. J. Neurochem. 75, 2221-2224.
27. Gibb W.R.G. (1993). The neuropathology of Parkinsonian disorders. In: Parkinson's Disease and Movement Disorders. 2nd ed. Jankovic J. and Tolosa E. (eds). Williams & Wilkins. pp 254-270.
28. Goldberg M.S. and Lansbury Jr P.T. (2000). Is there a cause-and-effect relationship between alpha-synuclein fibrillization and Parkinson's disease? Nat. Cell. Biol. 2, E115-E119.
29. Goldman J.E., Yen S.H., Chiu F.C. and Peress N.S. (1983). Lewy bodies of Parkinson's disease contain neurofilament antigens. Science 221, 1082-1084.
30. Gregori L., Hainfeld J.F., Simon M.N. and Goldgaber D. (1997). Binding of amyloid β protein to 20 S proteasome. J. Biol. Chem. 272, 58-62.
31. Gregori L., Fuchs C., Figueiredo-Pereira M.E., Van Nostrand W.E. and Goldgaber D. (1995). Amyloid beta-protein inhibits ubiquitin-dependent protein degradation in vitro. J. Biol. Chem. 270, 19702-19708.
32. Hamilton R.L. (2000). Lewy bodies in Alzheimer's disease: A neuropathological review of 145 cases using alpha-synuclein immunohistochemistry. Brain Pathol. 10, 378-384.
33. Hansen L.A. (1997). The Lewy body variant of Alzheimer disease. J. Neural Transm. Suppl. 51, 83-93.
34. Hashimoto M., Shu L.J., Sisk A., Xia Y., Takeda A., Sundsmo M. and Masliah E. (1998). Human recombinant NACP/alpha-synuclein is aggregated and fibrillated in vitro: Relevance for Lewy body disease. Brain Res. 799, 301-306.
35. Hicke L. (2001). Protein regulation by monoubiquitin. Nat. Rev. Mol. Cell Biol. 2, 195-201.
36. Hurtig H.I., Trojanowski J.Q., Galvin J., Ewbank D., Schmidt M.L., Lee V.M., Clark C.M., Glosser G., Stern M.B., Gollomp S.M. and Arnold S.E. (2000). Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease. Neurology 23, 1916-1921.
37. Ii K., Ito H., Tanaka K. and Hirano A. (1997). Immunocytochemical co-localization of the proteasome in ubiquitinated structures in neurodegenerative diseases and the elderly. J. Neuropathol. Exp. Neurol. 56, 125-131.
38. Imai Y., Soda M. and Takahashi R. (2000). Parkin suppresses unfolded protein stress-induced cell death through its E3 ubiquitin-protein ligase activity. J. Biol. Chem. 276, 35661-35664.
39. Imai Y., Soda M., Inoue H., Hattori N., Mizuno Y. and Takahashi R. (2001). An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of Parkin. Cell 105, 891-902.
40. Iwatsubo T., Yamaguchi H., Fujimuro M., Yokosawa H., Ihara Y., Trojanowski J.Q. and Lee V.M. (1996) Purification and characterization of Lewy bodies from the brains of patients with diffuse Lewy body disease. Am. J. Pathol. 148, 1517-1529.
41. Jana N.R., Zemskov E.A., Wang G.H. and Nukina N. (2001) Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release. Hum. Mol. Genet. 10, 1049-1059.
42. Keller J.N., Hanni K.B. and Markesbery W.R. (2000a). Impaired proteasome function in Alzheimer's disease. J. Neurochem. 75, 436-439.
43. Keller J.N., Hanni K.B. and Markesbery W.R. (2000b). Possible involvement of proteasome inhibition in aging: Implications for oxidative stress. Mech. Ageing Dev. 113, 61-70.
44. Keller J.N., Huang F.F. and Markesbery W.R. (2000c). Decreased levels of proteasome activity and proteasome expression in aging spinal cord. Neuroscience 98, 149-156.
45. Kitada T., Asakawa S., Hattori N., Matsumine H., Yamamura Y., Minoshima S., Yokochi M., Mizuno Y. and Shimizu N. (1998). Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392, 605-608
46. Klement I.A., Skinner P.J., Kaytor M.D., Yi H., Hersch S.M., Clark H.B., Zoghbi H.Y. and Orr H.T. (1998) Ataxin-1 nuclear localization and aggregation: Role in polyglutamine-induced disease in SCA1 transgenic mice. Cell 95, 41-53.
47. Kruger R., Kuhn W., Muller T., Woitalla D., Graeber M., Kosel S., Przuntek H., Epplen J.T., Schols L. and Riess O. (1998) Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Genet. 18, 106-108.
48. Kruger R., Eberhardt O., Riess O. and Schulz J.B. (2002). Parkinson's disease: One biochemical pathway to fit all genes? Trends Mol. Med. 8, 236-240.
49. Lam Y.A., Pickart C.M., Iban A., Landon M., Jamieson C., Ramage R., Mayer R.J. and Layfield R. (2000). Inhibition of the ubiquitin-proteasome system in Alzheimer's disease. Proc. Natl. Acad. Sci. USA 97, 9902-9906.
50. Larsen C.N., Krantz B.A. and Wilkinson K.D. (1998). Substrate specificity of deubiquitinating enzymes: Ubiquitin C-terminal hydrolases. Biochemistry 37, 3358-3368.
51. Larsen K.E. and Sulzer D. (2002). Autophagy in neurons: A review. Histol. Histopathol. 17, 897-908.
52. Layfield R. (2001) Does an inhibition of the ubiquitin/26S proteasome pathway of protein degradation underlie the pathogenesis of non-familial Alzheimer's disease? Med. Hypotheses 56, 395-399.
53. Lee M., Hyun D., Halliwell B. and Jenner P. (2001). Effect of the overexpression of wild-type or mutant alpha-synuclein on cell susceptibility to insult. J. Neurochem. 76, 998-1009.
54. Leroy E., Boyer R., Auburger G., Leube B., Ulm G., Mezey E., Harta G., Brownstein M.J., Jonnalagada S., Chernova T., Dehejia A., Lavedan C., Gasser T., Steinbach P.J., Wlkinson K.D. and Polymeropoulos M.H. (1998). The ubiquitin pathway in Parkinson's disease. Nature 395, 451-452.
55. Lindsten K., De Vrij F.M., Verhoef L.G., Fischer D.F., Van Leeuwen F.W., Hol E.M., Masucci M.G. and Dantuma N.P. (2002). Mutant ubiquitin found in neurodegenerative disorders is a ubiquitin fusion degradation substrate that blocks proteasomal degradation. J. Cell Biol. 157, 417-427.
56. Lippa C.F., Fujiwara H., Mann D.M., Giasson B., Baba M., Schmidt M.L., Nee L.E., O'Connell B., Pollen D.A., St George-Hyslop P., Ghetti B., Nochlin D., Bird T.D., Cairns N.J., Lee V.M., Iwatsubo T. and Trojanowski J.Q. (1998). Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes. Am. J. Pathol. 153, 1365-1370.
57. Lopes U., Ernhardt P., Yao R. and Cooper G. (1997). p53-dependent induction of apoptosis by proteasome inhibitors. J. Biol. Chem. 272, 12893-12896.
58. Lowe J., McDermott H., Landon M., Mayer R.J. and Wilkinson K.D. (1990). Ubiquitin carboxyl-terminal hydrolase (PGP 9.5) is selectively present in ubiquitinated inclusion bodies characteristics of human neurodegenerative diseases. J. Pathol. 161, 153-160.
59. Lucking C.B., Durr A., Bonifati V., Vaughan J., De Michele G., Gasser T., Harhangi B.S., Meco G., Denefle P., Wood N.W., Agid Y. and Brice A. (2000) Association between early-onset Parkinson's disease and mutations in the parkin gene. French Parkinson's Disease Genetics Study Group. N. Engl. J. Med. 342, 1560-1567.
60. Masliah E., Rockenstein E., Veinbergs I., Mallory M., Hashimoto M., Takeda A., Sagara Y., Sisk A. and Mucke L. (2000). Dopaminergic loss and inclusion body formation in alpha-synuclein mice: Implications for neurodegenerative disorders. Science 287, 1265-1269.
61. Mattila P.M., Rinne J.O., Helenius H., Dickson D.W. and Roytta M. (2000) Alpha-synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson's disease. Acta Neuropathol. (Berl) 100, 285-290.
62. McNaught K. and Jenner P. (2001) Proteasomal function is impaired in substantia nigra in Parkinson's disease. Neurosci. Lett. 297, 191-194.
63. McNaught K.S., Olanow C.W., Halliwell B., Isacson O. and Jenner P (2001) Failure of the ubiquitin-proteasome system in Parkinson's disease. Nature Rev. Neurosci. 2, 589-594.
64. McNaught K.S., Belizaire R., Jenner P. and Olanow C.W. and Isacson O. (2002a). Selective loss of 20S proteasome-subunits in the substantia nigra pars compacta in Parkinson's disease. Neurosci. Lett. 326, 155-158.
65. McNaught K.S., Mytilineou C., Jnobaptiste R., Yabut J., Shashidharan P., Jenner P. and Olanow C.W. (2002b). Impairment of the ubiquitin-proteasome system causes dopaminergic cell death and inclusion body formation in ventral mesencephalic cultures. J. Neurochem. 81, 301-306.
66. Meng L., Mohan R., Kwok B.H., Elofsson M., Sin N. and Crews C.M. (1999). Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Proc. Natl. Acad. Sci. USA 96, 10403-10897.
67. Mezey E., Reddy P.H., Dehejia A., Young T.A., Polymeropoulos M.H., Brownstein M.J. and Tagle D.A. (2000). Alpha-synuclein immunoreactivity of huntingtin polyglutamine aggregates in striatum and cortex of Huntington's disease patients and transgenic mouse models. Neurosci. Lett. 28, 289, 29-32.
68. Monney L., Otter I., Olivier R., Ozer H.L., Haas A.L., Omura S. and Borner C. (1998). Defects in the ubiquitin pathway induce caspase-independent apoptosis blocked by Bcl-2. J. Biol. Chem. 273, 6121-6131.
69. Papka M., Rubio A. and Schiffer R.B. (1998). A review of Lewy body disease, an emerging concept of cortical dementia. J. Neuropsychiatry Clin. Neurosci. 10, 267-279.
70. Park D.S., Levine B., Ferrari G. and Greene L.A. (1997). Cyclin-dependent kinase inhibitors and dominant negative cyclin-dependent kinase 4 and 6 promote survival of NGF-deprived sympathetic neurons. J. Neurosci. 17, 8975-8983.
71. Pasquini L.A., Moreno M.B., Adamo A.M., Pasquini J.M. and Soto E. (2000). Lactacystin, a specific inhibitor of the proteasome, induces apoptosis and activates caspase-3 in cultured cerebellar granule cells. J. Neurosci. Res. 59, 601-611.
72. Pickart C.M. (2000). Ubiquitin in chains. Trends Biochem. Sci. 25, 544-548.
73. Pickart C.M. (2001). Mechanisms underlying ubiquitination. Annu. Rev. Biochem. 70, 503-533
74. Pickart C.M. and Rose I.A. (1985). Ubiquitin carboxyl-terminal hydrolase acts on ubiquitin carboxyl-terminal amides. J. Biol. Chem. 260, 7903-7910
75. Piotrowski J., Beal R., Hoffman L., Wilkinson K.D., Cohen R.E. and Pickart C.M. (1997). Inhibition of the 26 S proteasome by polyubiquitin chains synthesized to have defined lengths. J. Biol. Chem. 272, 23712-23716.
76. Polymeropoulos, M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., Pike B., Root H., Rubenstein J., Boyer R., Stenroos E.S., Chandrasekharappa S., Athanassiadou A., Papapetropoulos T., Johnson W.G., Lazzarini A.M., Duvoisin R.C., Di Iorio G., Golbe L.I. and Nussbaum R.L. (1997). Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276, 2045-2047.
77. Qiu J.H., Asai A., Chi S., Saito N., Hamada H. and Kirino T. (2000). Proteasome inhibitors induce cytochrome c-caspase-3-like protease-mediated apoptosis in cultured cortical neurons. J. Neurosci. 20, 259-265.
78. Rideout H.J. and Stefanis L. (2002) Proteasomal inhibition-induced inclusion formation and death in cortical neurons require transcription and ubiquitination. Mol. Cell. Neurosci. 21, 223-238.
79. Rideout H.J., Larsen K.L., Sulzer D. and Stefanis L (2001). Proteasomal inhibition leads to formation of ubiquitin/a-synuclein-immunoreactive inclusions in PC12 cells. J. Neurochem. 78, 899-908.
80. Rideout H.J., Wang Q., Park D.S. and Stefanis L. (2003). Cyclin dependent kinase activity is required for apoptotic death but not inclusion formation in cortical neurons following proteasomal inhibition. J. Neurosci. (in press).
81. Saigoh K., Wang Y.L., Suh J.G., Yamanishi T., Sakai Y., Kiyosawa H., Harada T., Ichihara N., Wakana S., Kikuchi T. and Wada K. (1999). Intragenic deletion in the gene encoding ubiquitin carboxy-terminal hydrolase in gad mice. Nat. Genet. 23, 47-51.
82. Saudou F., Finbeiner S., Devy D. and Greenberg M. (1998). Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 95, 55-66.
83. Shimura H., Hattori N., Kubo S., Yoshikawa M., Kitada T., Matsumine H., Asakawa S., Minoshima S., Yamamura Y., Shimizu N. and Mizuno Y. (1999). Immunohistochemical and subcellular localization of Parkin protein: Absence of protein in autosomal recessive juvenile parkinsonism patients. Ann. Neurol. 45, 668-672.
84. Shimura H., Hattori N., Kubo Si., Mizuno Y., Asakawa S., Minoshima S., Shimizu N., Iwai K., Chiba T., Tanaka K. and Suzuki T. (2000). Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat. Genet. 25, 302-305.
85. Shimura H., Schlossmacher M.G., Hattori N., Frosch M.P., Trockenbacher A, Schneider R, Mizuno Y, Kosik K.S. and Selkoe D.J. (2001) Ubiquitination of a new form of alpha-synuclein by parkin from human brain: Implications for Parkinson's disease. Science 293, 263-269.
86. Sisodia S.S. (1998). Nuclear inclusions in glutamine repeat disorders: Are they pernicious, coincidental, or beneficial? Cell 95, 1-4.
87. Souza J.M., Giasson B.I., Lee V.M. and Ischiropoulos H. (2000). Chaperone-like activity of synucleins. FEBS Lett. 474, 116-119.
88. Spillantini M.G., Schmidt M.L., Lee V.M., Trojanowski J.Q., Jakes R. and Goedert M. (1997). Alpha-synuclein in Lewy bodies. Nature 388, 839-840.
89. Spillantini M.G., Crowther R.A., Jakes R., Hasegawa M. and Goedert M. (1998). Alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc. Natl. Acad. Sci. USA 95, 6469-6473.
90. Stefanis L, Larsen K.L., Rideout H.J., Sulzer D.S. and Greene L.A. (2001a). Expression of A53T mutant, but not wild type, α-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death. J. Neurosci. 21, 9549-9560.
91. Stefanis L., Kholodilov N., Rideout H.J., Burke R.E. an Greene L.A. (2001b). Synuclein-1 is selectively upregulated in response to NGF treatment in PC12 cells. J. Neurochem. 76, 1165-1176.
92. Tanaka Y., Engelender S., Igarashi S., Rao R.K., Wanner T., Tanzi R.E., Sawa A.L., Dawson V., Dawson T.M. and Ross C.A. (2001) Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. Hum. Mol. Genet. 10, 919-926.
93. Thrower J.S., Hoffman L., Rechsteiner M. and Pickart C.M. (2000.) Recognition of the polyubiquitin proteolytic signal. EMBO J. 19, 94-102.
94. Trojanowski J.Q., Goedert M., Iwatsubo T. and Lee V.M. (1998). Fatal attractions: Abnormal protein aggregation and neuron death in Parkinson's disease and Lewy body dementia. Cell Death Differ. 5, 832-837.
95. Van Leeuwen F.W., De Kleijn D.P.V., Van Den Hurk H.H., Neubauer A., Sonnemans M.A.F., Sluijs J.A., Koycu S., Ramdjielal R.D.J., Salehi A., Martens G.J.M., Grosveld F.G., Burbach J.P.H. and Hol E.M. (1998). Frameshift mutants of β amyloid precursor protein and ubiquitin-β in Alzheimer's and Down patients. Science 279, 242-247.
96. Zhang Y., Gao J., Chung K.K., Huang H., Dawson V.L. and Dawson T.M. (2000) Parkin functions as an E2-dependent ubiquitin-protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. Proc. Natl. Acad. Sci. USA 97, 13354-13359.